BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis 2016;29:319-29. [PMID: 27257797 DOI: 10.1097/QCO.0000000000000279] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 17.4] [Reference Citation Analysis]
Number Citing Articles
1 Gurevich E, Landau D. Pharmacological Management of Atypical Hemolytic Uremic Syndrome in Pediatric Patients: Current and Future. Paediatr Drugs 2023;:1-10. [PMID: 36637720 DOI: 10.1007/s40272-022-00555-6] [Reference Citation Analysis]
2 Osman M, Cohen Tervaert JW, Pagnoux C. Avacopan for the treatment of ANCA-associated vasculitis: an update. Expert Review of Clinical Immunology 2022. [DOI: 10.1080/1744666x.2023.2162041] [Reference Citation Analysis]
3 Gomes ABAGR, Feo LB, Silva GD, Disserol CCD, Paolilo RB, Lara AN, Tonácio AC, Mendes MF, Pereira SLA, Callegaro D. Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center's approach. Arq Neuropsiquiatr 2022;80:1057-66. [PMID: 36261129 DOI: 10.1055/s-0042-1754348] [Reference Citation Analysis]
4 Girmenia C, Barcellini W, Bianchi P, Di Bona E, Iori AP, Notaro R, Sica S, Zanella A, De Vivo A, Barosi G, Risitano A; scientific committee of the Associazione Italiana Emoglobinuria Parossistica Notturna (AIEPN). Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs. Blood Rev 2022;:101013. [PMID: 36117056 DOI: 10.1016/j.blre.2022.101013] [Reference Citation Analysis]
5 Szczepanik A, Choi D, Brady B, Chandran MM, Diamond A, Do V, Fredrick S, Kaiser T, Khalil K, Laub MR, Leino A, Park JM, Pierce D, Rendulic T, Wiegel JJ, Fose J, Jorgenson MR. The use of non-transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician. Clin Transplant 2022;:e14743. [PMID: 35690919 DOI: 10.1111/ctr.14743] [Reference Citation Analysis]
6 Ghosh K, Ghosh K. Monoclonal antibodies used for the management of haematological disorders. Expert Rev Hematol 2022. [PMID: 35504000 DOI: 10.1080/17474086.2022.2073213] [Reference Citation Analysis]
7 Mella A, Mariano F, Dolla C, Gallo E, Manzione AM, Di Vico MC, Cavallo R, De Rosa FG, Costa C, Biancone L. Bacterial and Viral Infection and Sepsis in Kidney Transplanted Patients. Biomedicines 2022;10:701. [DOI: 10.3390/biomedicines10030701] [Reference Citation Analysis]
8 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Lopez-medrano F, Silva JT. Timeline and Infectious Disease Evaluation of Candidates to New Therapies. Infectious Complications in Biologic and Targeted Therapies 2022. [DOI: 10.1007/978-3-031-11363-5_2] [Reference Citation Analysis]
10 Schweitzer L, Korsos V, Vinh DC. Treatment of Secondary Immunodeficiencies. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00175-0] [Reference Citation Analysis]
11 Blanchard-rohner G, Pittet LF. Vaccination Schedules in Immunocompromised Children. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-04844-9_5] [Reference Citation Analysis]
12 Rosenblatt J, Leung A, Baneman E, Fuller R, Taimur S, Paniz-Mondolfi AE, Malone AK, Kirkman L, Jacobs SE. Relapsed Babesia microti Infection Following Allogeneic Hematopoietic Cell Transplantation in a Patient With B-cell Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. Open Forum Infect Dis 2021;8:ofab323. [PMID: 34514015 DOI: 10.1093/ofid/ofab323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Yeaman MR. Immunosuppression in Glomerular Diseases: Implications for SARS-CoV-2 Vaccines and COVID-19. Glomerular Dis 2021;1:277-293. [DOI: 10.1159/000519182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Yang LP, Liu X, Zhang XH. [Advances in the diagnosis and management of transplant-associated thrombotic microangiopathy]. Zhonghua Xue Ye Xue Za Zhi 2021;42:693-9. [PMID: 34547882 DOI: 10.3760/cma.j.issn.0253-2727.2021.08.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ghosh K, Ghosh K. Monoclonal antibodies used for management of hematological disorders. JHAS 2021;1:12-21. [DOI: 10.25259/jhas_2_2021] [Reference Citation Analysis]
16 Babu TM, Kotton CN. Immunizations in Chronic Kidney Disease and Kidney Transplantation. Curr Treat Options Infect Dis 2021;:1-19. [PMID: 34025219 DOI: 10.1007/s40506-021-00248-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Classen AY, Henze L, von Lilienfeld-Toal M, Maschmeyer G, Sandherr M, Graeff LD, Alakel N, Christopeit M, Krause SW, Mayer K, Neumann S, Cornely OA, Penack O, Weißinger F, Wolf HH, Vehreschild JJ. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). Ann Hematol 2021;100:1603-20. [PMID: 33846857 DOI: 10.1007/s00277-021-04452-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
18 Карпов И. An Uninvited Guest: Meningococcal Infection – Current Aspects of Epidemiology, Clinic and Prevention. Клиническая инфектология и паразитология 2021. [DOI: 10.34883/pi.2021.10.1.024] [Reference Citation Analysis]
19 Mülling N, Rohn H, Vogel U, Claus H, Wilde B, Eisenberger U, Kribben A, Witzke O, Gäckler A. Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome. Biosci Rep 2020;40:BSR20200177. [PMID: 32159209 DOI: 10.1042/BSR20200177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Pittet LF, Posfay-Barbe KM. Vaccination of immune compromised children-an overview for physicians. Eur J Pediatr 2021;180:2035-47. [PMID: 33665677 DOI: 10.1007/s00431-021-03997-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
21 Bjanes E, Nizet V. More than a Pore: Nonlytic Antimicrobial Functions of Complement and Bacterial Strategies for Evasion. Microbiol Mol Biol Rev 2021;85:e00177-20. [PMID: 33504655 DOI: 10.1128/MMBR.00177-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Mueller NJ. Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_13] [Reference Citation Analysis]
23 Bulavko IE, Timofeev EV, Alkak KJU, Isakov VA. Scleroderma nephropathy: unsolved problems. Juvenis scientia 2021;7:5-18. [DOI: 10.32415/jscientia_2021_7_5_5-18] [Reference Citation Analysis]
24 Harshman LA, Bartosh SM. Recurrent Disease Challenges in Pediatric Kidney Transplantation. Challenges in Pediatric Kidney Transplantation 2021. [DOI: 10.1007/978-3-030-74783-1_8] [Reference Citation Analysis]
25 Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, Chase J, Liebling EJ, Burudpakdee C, Lee JH, Balamuth FB, Blatz AM, Chiotos K, Fitzgerald JC, Giglia TM, Gollomp K, Odom John AR, Jasen C, Leng T, Petrosa W, Vella LA, Witmer C, Sullivan KE, Laskin BL, Hensley SE, Bassiri H, Behrens EM, Teachey DT. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv 2020;4:6051-63. [PMID: 33290544 DOI: 10.1182/bloodadvances.2020003471] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 22.7] [Reference Citation Analysis]
26 Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96:114-22. [PMID: 33144515 DOI: 10.1212/WNL.0000000000011124] [Cited by in Crossref: 95] [Cited by in F6Publishing: 103] [Article Influence: 31.7] [Reference Citation Analysis]
27 Gavriilaki M, Kimiskidis VK, Gavriilaki E. Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics. Pharmaceuticals (Basel) 2020;13:E341. [PMID: 33114553 DOI: 10.3390/ph13110341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
28 Galstyan GM. Coagulopathy in COVID-19. Pulʹmonologiâ (Mosk ) 2020;30:645-657. [DOI: 10.18093/0869-0189-2020-30-5-645-657] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
29 Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat Rev Neurol 2020;16:601-17. [PMID: 33005040 DOI: 10.1038/s41582-020-0400-0] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 23.3] [Reference Citation Analysis]
30 Calabrese LH, Calabrese C, Lenfant T, Kirchner E, Strand V. Infections in the Era of Targeted Therapies: Mapping the Road Ahead. Front Med (Lausanne) 2020;7:336. [PMID: 32974356 DOI: 10.3389/fmed.2020.00336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gauchy AC, Hentzien M, Wynckel A, de Marcellus V, Rodier C, Delmer A, Quinquenel A. Efficacy of eculizumab in refractory life-threatening warm autoimmune hemolytic anemia associated with chronic myelomonocytic leukemia. Clin Case Rep 2020;8:2641-4. [PMID: 33363796 DOI: 10.1002/ccr3.3250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
32 Klämbt V, Gimpel C, Bald M, Gerken C, Billing H, Loos S, Hansen M, König J, Vinke T, Montoya C, Sperandio BL, Kirschstein M, Hennies I, Pohl M, Häffner K. Different approaches to long-term treatment of aHUS due to MCP mutations: a multicenter analysis. Pediatr Nephrol 2021;36:463-71. [PMID: 32715379 DOI: 10.1007/s00467-020-04714-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Pawlitzki M, Zettl UK, Ruck T, Rolfes L, Hartung H, Meuth SG. Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie. DGNeurologie 2020;3:285-297. [DOI: 10.1007/s42451-020-00205-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 von Samson-himmelstjerna FA, Feldkamp T, Witzke O. Infektiöse Komplikationen bei Nierentransplantation. Nephrologe 2020;15:216-224. [DOI: 10.1007/s11560-020-00433-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Pawlitzki M, Zettl UK, Ruck T, Rolfes L, Hartung HP, Meuth SG. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19. EBioMedicine 2020;56:102822. [PMID: 32535547 DOI: 10.1016/j.ebiom.2020.102822] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
36 Owoicho O, Olwal CO, Quaye O. Commentary: An enzymatic pathway in the human gut microbiome that converts A to universal O type blood. Front Immunol 2020;11:772. [PMID: 32411149 DOI: 10.3389/fimmu.2020.00772] [Reference Citation Analysis]
37 Özge Özcan Ö, Karahan M, Vijayaraj Kumar P, Leng Tan S, Na Tee Y. New Generation Peptide-Based Vaccine Prototype. Current and Future Aspects of Nanomedicine 2020. [DOI: 10.5772/intechopen.89115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Seibel J, Rebibou J, Bonnot P, Bernard A, Zanetta G, Tetu J, Legendre M. Fusobacterium nucleatum bacteremia with pneumopathy in a patient receiving eculizumab: A case report. Anaerobe 2020;61:102099. [DOI: 10.1016/j.anaerobe.2019.102099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Le Guennec L, Bourdoulous S. Pyogenic Infections of the CNS 1. Infections of the Central Nervous System 2020. [DOI: 10.1002/9781119467748.ch30] [Reference Citation Analysis]
40 Mueller NJ. Changing Definition of Immunosuppression: Targeted Therapies and Resulting Emerging Infections and Their Prevention. Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_13-1] [Reference Citation Analysis]
41 Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice. BMC Nephrol 2019;20:424. [PMID: 31752725 DOI: 10.1186/s12882-019-1599-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
42 Lu E, Moore W. The PLASMIC Score May Be Useful in the Early Diagnosis of Complement-Mediated Thrombotic Microangiopathy via Early Exclusion of Thrombotic Thrombocytopenic Purpura. Case Reports in Medicine 2019;2019:1-3. [DOI: 10.1155/2019/9180810] [Reference Citation Analysis]
43 Stevens NE, Cowin AJ, Kopecki Z. Skin Barrier and Autoimmunity-Mechanisms and Novel Therapeutic Approaches for Autoimmune Blistering Diseases of the Skin. Front Immunol 2019;10:1089. [PMID: 31156638 DOI: 10.3389/fimmu.2019.01089] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
44 Holmdahl R, Nimmerjahn F, Ludwig RJ. Editorial: Autoantibodies. Front Immunol 2019;10:484. [PMID: 31001243 DOI: 10.3389/fimmu.2019.00484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
45 Meuth SG, Pawlitzki M. Was kann die Antikörpertherapie in der Neurologie? DNP 2019;20:20-29. [DOI: 10.1007/s15202-019-2169-9] [Reference Citation Analysis]
46 Stefanovic V. The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? J Clin Med 2019;8:E407. [PMID: 30909646 DOI: 10.3390/jcm8030407] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
47 Burns E, Anand K, Acosta G, Irani M, Chung B, Maiti A, Ibrahim I, Rice L. Autosplenectomy in a Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH). Case Rep Hematol 2019;2019:3146965. [PMID: 30891320 DOI: 10.1155/2019/3146965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019;129:1061-75. [PMID: 30714990 DOI: 10.1172/JCI99296] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
49 Reyes LC, Saland JM. Hemolytic Uremic Syndrome, Genetic. Glomerulonephritis 2019. [DOI: 10.1007/978-3-319-49379-4_43] [Reference Citation Analysis]
50 Whitaker JA, Valles K, Tosh PK, Poland GA. Vaccine Use in Immunocompromised Adults. Vaccinations 2019. [DOI: 10.1016/b978-0-323-55435-0.00009-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Peremiquel-trillas P, Leguízamo LM, Asensio Ostos C, Martínez-gómez X. Vaccines that should be administered to patients receiving treatment with immunosuppressive, immunomodulatory and/or biological drugs. Medicina Clínica (English Edition) 2018;151:498-502. [DOI: 10.1016/j.medcle.2018.05.046] [Reference Citation Analysis]
52 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
53 Martinez-Mera C, Montes-Torres A, Gordillo-Vélez C, Sánchez-Pérez J. Ecthyma Gangrenosum in Paroxysmal Nocturnal Hemoglobinuria. Acta Haematol 2018;140:166-8. [PMID: 30300881 DOI: 10.1159/000492739] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications. J Innate Immun 2018;10:455-64. [PMID: 30149378 DOI: 10.1159/000491439] [Cited by in Crossref: 70] [Cited by in F6Publishing: 76] [Article Influence: 14.0] [Reference Citation Analysis]
55 Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2019;34:1485-92. [PMID: 30058046 DOI: 10.1007/s00467-018-4025-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 4.6] [Reference Citation Analysis]
56 Jefferson JA. Complications of Immunosuppression in Glomerular Disease. Clin J Am Soc Nephrol 2018;13:1264-75. [PMID: 30042223 DOI: 10.2215/CJN.01920218] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
57 Tomlinson S, Thurman JM. Tissue-targeted complement therapeutics. Mol Immunol 2018;102:120-8. [PMID: 30220307 DOI: 10.1016/j.molimm.2018.06.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
58 Dumas G, Bigé N, Lemiale V, Azoulay E. Patients immunodéprimés, quel pathogène pour quel déficit immunitaire ? (en dehors de l’infection à VIH). Méd Intensive Réa 2018;27:344-366. [DOI: 10.3166/rea-2018-0056] [Reference Citation Analysis]
59 Kawanishi T, Hasegawa J, Kono M, Ishiwatari A, Ogawa T, Abe Y, Endo M, Ishigooka H, Okumi M, Tanabe K, Wakai S, Shirakawa H. Thrombotic microangiopathy after kidney transplantation successfully treated with eculizumab: A case report. Transplantation Reports 2018;3:5-8. [DOI: 10.1016/j.tpr.2018.03.002] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Reyes LC, Saland JM. Hemolytic Uremic Syndrome, Genetic. Glomerulonephritis 2018. [DOI: 10.1007/978-3-319-27334-1_43-1] [Reference Citation Analysis]
61 Cohen C. Background and Presentation of Thrombotic Thrombocytopenic Purpura. Immune Hematology 2018. [DOI: 10.1007/978-3-319-73269-5_8] [Reference Citation Analysis]
62 Abreu C, Sarmento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. Dig Liver Dis 2017;49:1289-97. [PMID: 28986117 DOI: 10.1016/j.dld.2017.09.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
63 Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol 2018;18:46-61. [PMID: 29063907 DOI: 10.1038/nri.2017.106] [Cited by in Crossref: 340] [Cited by in F6Publishing: 345] [Article Influence: 56.7] [Reference Citation Analysis]
64 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 148] [Cited by in F6Publishing: 160] [Article Influence: 24.7] [Reference Citation Analysis]
65 Kawakami T, Nakazawa H, Kurasawa Y, Sakai H, Nishina S, Senoo N, Senoo Y, Ishida F. Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. Intern Med 2018;57:127-30. [PMID: 29021487 DOI: 10.2169/internalmedicine.9151-17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
66 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
67 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
68 Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, Pawar R, Chugh S. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Exp Hematol Oncol 2017;6:4. [PMID: 28101432 DOI: 10.1186/s40164-017-0064-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]